NCT00777530

Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects

Ascending Single-Dose Of The Safety, Tolerability, And Pharmacokinetics Of Bosutinib Administered Orally With Multiple Doses Of Ketoconazole To Healthy Adult Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the safety and tolerability of ascending single oral doses of bosutinib administered with multiple doses of ketoconazole and to provide the pharmacokinetic profile of bosutinib when administered with multiple doses of ketoconazole and with food in healthy adult subjects.

Conditions

• Breast Cancer
• Tumors
• Leukemia

Interventions

Type	Name	Description
DRUG	Bosutinib (SKI-606)

Timeline

• Start date: 2008-04-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2008-10-22
• Last updated: 2008-10-23

Locations

1 site across 1 country: Netherlands